BLACK DIAMOND THERAPEUTICS, INC. Investing Cash Flow
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Investing Cash Flow of $16.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-05
- BLACK DIAMOND THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$3.12M.
- BLACK DIAMOND THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $19.50M, a 128.15% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$2.89M, a 110.40% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $8.59M, a 291.70% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$44.91M, a 364.65% decline from fiscal 2024.
- BLACK DIAMOND THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2024 was $16.97M, a 3.81% increase from fiscal 2023.
- BLACK DIAMOND THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2023 was $16.35M, a 69.37% decline from fiscal 2022.
- BLACK DIAMOND THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2022 was $53.37M, a 59.14% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $16.38M 10-Q · filed 2026-08-05 | $13.49M derived: sum of 3 quarters · filed 2026-08-05 | $22.08M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $19.50M 10-Q · filed 2026-05-07 | $16.61M derived: sum of 2 quarters · filed 2026-05-07 | $25.20M derived: sum of 3 quarters · filed 2026-05-07 | -$33.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$2.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $5.70M derived: sum of 2 quarters · filed 2026-03-16 | -$53.45M derived: sum of 3 quarters · filed 2026-08-05 | -$44.91M 10-K · filed 2026-03-16 |
| 2025-09-30 | $8.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$50.56M derived: sum of 2 quarters · filed 2026-08-05 | -$42.02M 10-Q · filed 2025-11-06 | -$14.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$59.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$50.61M 10-Q · filed 2026-08-05 | -$22.84M derived: sum of 3 quarters · filed 2026-08-05 | -$20.64M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $8.55M 10-Q · filed 2026-05-07 | $36.32M derived: sum of 2 quarters · filed 2026-05-07 | $38.51M derived: sum of 3 quarters · filed 2026-05-07 | $39.25M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $27.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $29.96M derived: sum of 2 quarters · filed 2026-03-16 | $30.70M derived: sum of 3 quarters · filed 2026-03-16 | $16.97M 10-K · filed 2026-03-16 |
| 2024-09-30 | $2.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.93M derived: sum of 2 quarters · filed 2025-11-06 | -$10.80M 10-Q · filed 2025-11-06 | $1.45M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $740.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$12.99M 10-Q · filed 2025-08-07 | -$745.00K derived: sum of 3 quarters · filed 2025-08-07 | -$38.63M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$13.73M 10-Q · filed 2025-05-12 | -$1.49M derived: sum of 2 quarters · filed 2025-05-12 | -$39.37M derived: sum of 3 quarters · filed 2025-05-12 | -$22.19M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $12.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$25.64M derived: sum of 2 quarters · filed 2025-03-06 | -$8.46M derived: sum of 3 quarters · filed 2025-03-06 | $16.35M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$37.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$20.71M derived: sum of 2 quarters · filed 2024-11-05 | $4.10M 10-Q · filed 2024-11-05 | $6.42M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $17.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $41.98M 10-Q · filed 2024-08-06 | $44.30M derived: sum of 3 quarters · filed 2024-08-06 | $58.81M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $24.81M 10-Q · filed 2024-05-09 | $27.13M derived: sum of 2 quarters · filed 2024-05-09 | $41.63M derived: sum of 3 quarters · filed 2024-05-09 | $61.44M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $2.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $16.83M derived: sum of 2 quarters · filed 2024-03-12 | $36.64M derived: sum of 3 quarters · filed 2024-03-12 | $53.37M 10-K · filed 2024-03-12 |
| 2022-09-30 | $14.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $34.31M derived: sum of 2 quarters · filed 2023-11-06 | $51.04M 10-Q · filed 2023-11-06 | $94.29M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $19.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $36.54M 10-Q · filed 2023-08-11 | $79.78M derived: sum of 3 quarters · filed 2023-08-11 | $115.48M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $16.73M 10-Q · filed 2023-05-09 | $59.97M derived: sum of 2 quarters · filed 2023-05-09 | $95.67M derived: sum of 3 quarters · filed 2023-05-09 | $143.87M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $43.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $78.94M derived: sum of 2 quarters · filed 2023-03-09 | $127.14M derived: sum of 3 quarters · filed 2023-03-09 | $130.61M 10-K · filed 2023-03-09 |
| 2021-09-30 | $35.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $83.90M derived: sum of 2 quarters · filed 2022-11-08 | $87.37M 10-Q · filed 2022-11-08 | $80.72M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $48.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $51.67M 10-Q · filed 2022-08-09 | $45.03M derived: sum of 3 quarters · filed 2022-08-09 | $49.62M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $3.47M 10-Q · filed 2022-05-11 | -$3.17M derived: sum of 2 quarters · filed 2022-05-11 | $1.42M derived: sum of 3 quarters · filed 2022-05-11 | -$278.22M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | -$6.65M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$2.05M derived: sum of 2 quarters · filed 2022-03-17 | -$281.69M derived: sum of 3 quarters · filed 2022-03-17 | -$281.69M 10-K · filed 2022-03-17 |
| 2020-09-30 | $4.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$275.04M derived: sum of 2 quarters · filed 2021-11-08 | -$275.04M 10-Q · filed 2021-11-08 | -$275.05M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | -$279.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$279.64M 10-Q · filed 2021-08-12 | -$279.64M derived: sum of 3 quarters · filed 2021-08-12 | -$279.65M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-07 | -$2.00K derived: sum of 2 quarters · filed 2021-05-07 | -$13.00K derived: sum of 3 quarters · filed 2021-05-07 | -$11.00K derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$13.00K derived: sum of 2 quarters · filed 2021-03-25 | -$11.00K derived: sum of 3 quarters · filed 2021-03-25 | -$21.00K 10-K · filed 2021-03-25 |
| 2019-09-30 | -$11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$9.00K derived: sum of 2 quarters · filed 2020-11-10 | -$19.00K 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | -$8.00K 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | -$10.00K 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | -$76.00K 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |